We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Prophylactic Pacemakers After TAVR: Low Pacing Burden Raises Questions on Routine Use

MedXY Editorial Team•Dec 17, 2025•Cardiology
CardiologyTAVR

Highlight

  • Prophylactic permanent pacemakers (PPI) are implanted in about 24% of TAVR patients requiring pacing.
  • Primary indication is persistent left bundle branch block with marked PR/QRS prolongation.
  • 30-day pacing burden is significantly lower in prophylactic PPI patients compared to non-prophylactic PPI recipients.
  • Findings challenge the rationale for routine prophylactic PPI post-TAVR.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: Evidence and Insights from the NOTION-4 TrialThe NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding riskSep 1, 2026The Second Universal Definition of Heart Failure (2026): What Clinicians and Health Systems Need to KnowA clear, global update standardizing heart failure terminology, phenotypes, causes, and trajectories to improve prevention, diagnosis, treatment, and global surveillance.Aug 25, 2026Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 TrialIn low-risk severe aortic stenosis patients, both TAVR and SAVR provide sustained health status improvements over seven years, with TAVR offering faster early recovery but similar long-term health outcomes.Aug 18, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Seven-Year Valve Durability Outcomes Comparing Transcatheter and Surgical Aortic Valve Replacement: Insights from the PARTNER 3 Randomized Trial
An evidence-based review of the 7-year durability of transcatheter versus surgical aortic bioprosthetic valves in low-risk severe aortic stenosis patients, highlighting comparable long-term structural performance and need for reintervention
Jun 24, 2026
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis: What PARTNER 2A Adds to the Long-Term TAVR Evidence BaseThe PARTNER 2A 10-year data show higher mortality and reintervention with balloon-expandable SAPIEN XT TAVR versus surgery in intermediate-risk patients, driven mainly by transthoracic access. Contemporary 10-year SAPIEN 3 data, however, suJun 17, 2026
Can a Sirolimus-Eluting Balloon Reduce Stent Use in De Novo Coronary Disease? New Randomized Evidence from SELUTION DeNovoA large randomized trial found sirolimus-eluting balloon with provisional stenting noninferior to routine DES at 1 year by intention-to-treat analysis, though repeat revascularization was slightly higher and per-protocol noninferiority was Jun 19, 2026